Newsbenzinga
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
· Published
Article summary
Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
An excerpt from the original article.
Comments —
Loading comments…